CoChat

The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis

Commons, Robert J, Simpson, Julie A, Thriemer, Kamala, Humphreys, Georgina S, Abreha, Tesfay, Alemu, Sisay G, Añez, Arletta, Anstey, Nicholas M, Awab, Ghulam R, Baird, J Kevin, Barber, Bridget E, Borghini-Fuhrer, Isabelle, Chu, Cindy S, D'Alessandro, Umberto, Dahal, Prabin, Daher, André, de Vries, Peter J, Erhart, Annette, Gomes, Margarete S M, Gonzalez-Ceron, Lilia, Grigg, Matthew J, Heidari, Aliehsan, Hwang, Jimee, Kager, Piet A, Ketema, Tsige, Khan, Wasif A, Lacerda, Marcus V G, Leslie, Toby, Ley, Benedikt, Lidia, Kartini, Monteiro, Wuelton M, Nosten, Francois, Pereira, Dhelio B, Phan, Giao T, Phyo, Aung P, Rowland, Mark, Saravu, Kavitha, Sibley, Carol H, Siqueira, André M, Stepniewska, Kasia, Sutanto, Inge, Taylor, Walter R J, Thwaites, Guy, Tran, Binh Q, Tran, Hien T, Valecha, Neena, Vieira, José Luiz F, Wangchuk, Sonam, William, Timothy, Woodrow, Charles J, Zuluaga-Idarraga, Lina, Guerin, Philippe J, White, Nicholas J, Price, Ric N · 2018 · The Lancet Infectious Diseases
Cited by 102

The DOI matches its Crossref record.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(18)30348-7

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 65

  1. Coatney, 1963, Pitfalls in a discovery: the chronicle of chloroquine, Am J Trop Med Hyg, 12, 121, 10.4269/ajtmh.1963.12.121 · DOI · Paper page
  2. Baird, 2004, Chloroquine resistance in Plasmodium vivax, Antimicrob Agents Chemother, 48, 4075, 10.1128/AAC.48.11.4075-4083.2004 · DOI · Paper page
  3. Rieckmann, 1989, Plasmodium vivax resistance to chloroquine?, Lancet, 2, 1183, 10.1016/S0140-6736(89)91792-3 · DOI · Paper page
  4. Wellems, 2001, Chloroquine-resistant malaria, J Infect Dis, 184, 770, 10.1086/322858 · DOI · Paper page
  5. Price, 2014, Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis, Lancet Infect Dis, 14, 982, 10.1016/S1473-3099(14)70855-2 · DOI · Paper page
  6. Douglas, 2013, Major burden of severe anemia from non-falciparum malaria species in southern Papua: a hospital-based surveillance study, PLoS Med, 10, e1001575, 10.1371/journal.pmed.1001575 · DOI · Paper page
  7. Price, 2009, New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance, Curr Opin Infect Dis, 22, 430, 10.1097/QCO.0b013e32832f14c1 · DOI · Paper page
  8. Douglas, 2012, Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria, Adv Parasitol, 80, 271, 10.1016/B978-0-12-397900-1.00005-0 · DOI
  9. Egan, 2007, Strategies to reverse drug resistance in malaria, Curr Opin Infect Dis, 20, 598, 10.1097/QCO.0b013e3282f1673a · DOI
  10. Berliner, 1948, Studies on the chemotherapy of the human malarias. Vi. The physiological disposition, antimalarial activity, and toxicity of several derivatives of 4-aminoquinoline, J Clin Invest, 27, 98, 10.1172/JCI101980 · doi:10.1172/jci101980
  11. Abreha, 2017, Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial, PLoS Med, 14, e1002299, 10.1371/journal.pmed.1002299 · DOI · Paper page
  12. Luxemburger, 1999, Treatment of vivax malaria on the western border of Thailand, Trans R Soc Trop Med Hyg, 93, 433, 10.1016/S0035-9203(99)90149-9 · DOI
  13. Commons, 2017, The Vivax Surveyor: online mapping database for Plasmodium vivax clinical trials, Int J Parasitol Drugs Drug Resist, 7, 181, 10.1016/j.ijpddr.2017.03.003 · DOI
  14. Gething, 2012, A long neglected world malaria map: Plasmodium vivax endemicity in 2010, PLoS Negl Trop Dis, 6, e1814, 10.1371/journal.pntd.0001814 · DOI · Paper page
  15. Battle, 2014, Geographical variation in Plasmodium vivax relapse, Malar J, 13, 144, 10.1186/1475-2875-13-144 · DOI · Paper page
  16. Taylor, 2001, Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia, Am J Trop Med Hyg, 64, 223, 10.4269/ajtmh.2001.64.223 · DOI
  17. Phan, 2002, Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam, Trop Med Int Health, 7, 858, 10.1046/j.1365-3156.2002.00948.x · DOI
  18. Valecha, 2006, Therapeutic efficacy of chloroquine in Plasmodium vivax from areas with different epidemiological patterns in India and their Pvdhfr gene mutation pattern, Trans R Soc Trop Med Hyg, 100, 831, 10.1016/j.trstmh.2005.11.012 · DOI
  19. Leslie, 2007, Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial, JAMA, 297, 2201, 10.1001/jama.297.20.2201 · doi:10.1001/jama.297.20.2201
  20. Ratcliff, 2007, Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia, Trans R Soc Trop Med Hyg, 101, 351, 10.1016/j.trstmh.2006.06.008 · DOI · Paper page
  21. Guthmann, 2008, Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar, Trop Med Int Health, 13, 91, 10.1111/j.1365-3156.2007.01978.x · DOI
  22. Leslie, 2008, A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan, PLoS One, 3, e2861, 10.1371/journal.pone.0002861 · DOI
  23. Ketema, 2009, Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia, Malar J, 8, 177, 10.1186/1475-2875-8-177 · DOI
  24. Sutanto, 2009, Resistance to chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in eastern Indonesia, Am J Trop Med Hyg, 81, 338, 10.4269/ajtmh.2009.81.338 · doi:10.4269/ajtmh.2009.81.338
  25. Awab, 2010, Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial, Malar J, 9, 105, 10.1186/1475-2875-9-105 · DOI
  26. Sutanto, 2010, Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia, Malar J, 9, 52, 10.1186/1475-2875-9-52 · DOI
  27. Phyo, 2011, Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial, Clin Infect Dis, 53, 977, 10.1093/cid/cir631 · DOI · Paper page
  28. Poravuth, 2011, Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial, PLoS One, 6, e14501, 10.1371/journal.pone.0014501 · DOI
  29. Mishra, 2012, Monitoring antimalarial drug resistance in India via sentinel sites: outcomes and risk factors for treatment failure, 2009–2010, Bull World Health Organ, 90, 895, 10.2471/BLT.12.109124 · DOI
  30. Barber, 2013, A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy, Clin Infect Dis, 56, 383, 10.1093/cid/cis902 · DOI · Paper page
  31. Hwang, 2013, In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia, PLoS One, 8, e63433, 10.1371/journal.pone.0063433 · doi:10.1371/journal.pone.0063433
  32. Marques, 2014, Plasmodium vivax chloroquine resistance and anemia in the western Brazilian Amazon, Antimicrob Agents Chemother, 58, 342, 10.1128/AAC.02279-12 · DOI
  33. Anez, 2015, Resistance of infection by Plasmodium vivax to chloroquine in Bolivia, Malar J, 14, 261, 10.1186/s12936-015-0774-4 · DOI
  34. Getachew, 2015, Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia, Malar J, 14, 525, 10.1186/s12936-015-1041-4 · DOI · Paper page
  35. Gomes, 2015, Efficacy in the treatment of malaria by Plasmodium vivax in Oiapoque, Brazil, on the border with French Guiana: the importance of control over external factors, Malar J, 14, 402, 10.1186/s12936-015-0925-7 · doi:10.1186/s12936-015-0925-7
  36. Gonzalez-Ceron, 2015, Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico, Malar J, 14, 426, 10.1186/s12936-015-0938-2 · DOI
  37. Lidia, 2015, Therapeutic effects of dyhidroartemisinin piperaquine versus chloroquine for uncomplicated vivax malaria in Kupang, East Nusa Tenggara, Indonesia, Int J Pharm Sci Rev Res, 31, 247
  38. Rishikesh, 2015, Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India, Malar J, 14, 310, 10.1186/s12936-015-0824-y · DOI
  39. Thanh, 2015, Confirmed Plasmodium vivax resistance to chloroquine in central Vietnam, Antimicrob Agents Chemother, 59, 7411, 10.1128/AAC.00791-15 · DOI
  40. Grigg, 2016, Efficacy of artesunate-mefloquine for chloroquine-resistant Plasmodium vivax malaria in Malaysia: an open-label, randomized, controlled trial, Clin Infect Dis, 62, 1403, 10.1093/cid/ciw121 · DOI
  41. Ley, 2016, G6PD deficiency and antimalarial efficacy for uncomplicated malaria in Bangladesh: a prospective observational study, PLoS One, 11, e0154015, 10.1371/journal.pone.0154015 · DOI
  42. Pereira, 2016, Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment, Malar J, 15, 477, 10.1186/s12936-016-1530-0 · DOI
  43. Saravu, 2016, Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from primary care centres in southwestern India, PLoS One, 11, e0157666, 10.1371/journal.pone.0157666 · DOI · Paper page
  44. Thuan, 2016, A randomized comparison of chloroquine versus dihydroartemisinin-piperaquine for the treatment of Plasmodium vivax infection in Vietnam, Am J Trop Med Hyg, 94, 879, 10.4269/ajtmh.15-0740 · doi:10.4269/ajtmh.15-0740
  45. Wangchuk, 2016, Where chloroquine still works: the genetic make-up and susceptibility of Plasmodium vivax to chloroquine plus primaquine in Bhutan, Malar J, 15, 277, 10.1186/s12936-016-1320-8 · DOI
  46. Zuluaga-Idarraga, 2016, Prospective study of Plasmodium vivax malaria recurrence after radical treatment with a chloroquine-primaquine standard regimen in Turbo, Colombia, Antimicrob Agents Chemother, 60, 4610, 10.1128/AAC.00186-16 · DOI
  47. Siqueira, 2017, Fixed-dose artesunate-amodiaquine combination vs chloroquine for treatment of uncomplicated blood stage P. vivax infection in the Brazilian Amazon: an open-label randomized, controlled trial, Clin Infect Dis, 64, 166, 10.1093/cid/ciw706 · DOI
  48. Heidari, 2012, In vivo susceptibility of Plasmodium vivax to chloroquine in southeastern Iran, Iran J Parasitol, 7, 8
  49. Douglas, 2010, Artemisinin combination therapy for vivax malaria, Lancet Infect Dis, 10, 405, 10.1016/S1473-3099(10)70079-7 · DOI · Paper page
  50. Thriemer, 2017, Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group, Malar J, 16, 141, 10.1186/s12936-017-1784-1 · DOI · Paper page
  51. Douglas, 2017, Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: a hospital-based cohort study, PLoS Med, 14, e1002379, 10.1371/journal.pmed.1002379 · DOI · Paper page
  52. Ursing, 2014, Chloroquine is grossly under dosed in young children with malaria: implications for drug resistance, PLoS One, 9, e86801, 10.1371/journal.pone.0086801 · doi:10.1371/journal.pone.0086801
  53. Obua, 2008, Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen, Br J Clin Pharmacol, 65, 493, 10.1111/j.1365-2125.2007.03050.x · doi:10.1111/j.1365-2125.2007.03050.x
  54. Zhao, 2014, Population pharmacokinetics of azithromycin and chloroquine in healthy adults and paediatric malaria subjects following oral administration of fixed-dose azithromycin and chloroquine combination tablets, Malar J, 13, 36, 10.1186/1475-2875-13-36 · doi:10.1186/1475-2875-13-36
  55. Añez, 2016, Evaluation of the paediatric dose of chloroquine in the treatment of Plasmodium vivax malaria, Malar J, 15, 371, 10.1186/s12936-016-1420-5 · doi:10.1186/s12936-016-1420-5
  56. Kofoed, 2002, Treatment of children with Plasmodium falciparum malaria with chloroquine in Guinea-Bissau, Am J Trop Med Hyg, 67, 28, 10.4269/ajtmh.2002.67.28 · doi:10.4269/ajtmh.2002.67.28
  57. Kofoed, 2007, Different doses of amodiaquine and chloroquine for treatment of uncomplicated malaria in children in Guinea-Bissau: implications for future treatment recommendations, Trans R Soc Trop Med Hyg, 101, 231, 10.1016/j.trstmh.2006.05.008 · DOI
  58. Ursing, 2016, High-dose chloroquine for treatment of chloroquine-resistant Plasmodium falciparum Malaria, J Infect Dis, 213, 1315, 10.1093/infdis/jiv590 · doi:10.1093/infdis/jiv590
  59. Ursing, 2009, Chloroquine is grossly overdosed and overused but well tolerated in Guinea-Bissau, Antimicrob Agents Chemother, 53, 180, 10.1128/AAC.01111-08 · doi:10.1128/aac.01111-08
  60. Scragg, 1968, Emetine hydrochloride and dehydroemetine combined with chloroquine in the treatment of children with amoebic liver abscess, Arch Dis Child, 43, 121, 10.1136/adc.43.227.121 · doi:10.1136/adc.43.227.121
  61. Canete, 2010, A randomized, controlled, open-label trial evaluating the efficacy and safety of chloroquine in the treatment of giardiasis in children, West Indian Med J, 59, 607
  62. Price, 2012, Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax, Trends Parasitol, 28, 522, 10.1016/j.pt.2012.08.005 · DOI
  63. White, 2002, The assessment of antimalarial drug efficacy, Trends Parasitol, 18, 458, 10.1016/S1471-4922(02)02373-5 · DOI · Paper page
  64. Flegg, 2011, Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator, Malar J, 10, 339, 10.1186/1475-2875-10-339 · DOI · Paper page
  65. Stepniewska, 2010, In vivo parasitological measures of artemisinin susceptibility, J Infect Dis, 201, 570, 10.1086/650301 · DOI · Paper page

Cited by

See all 102

Metadata

Authors
Commons, R. J., Simpson, J. A., Thriemer, K., Humphreys, G. S., Abreha, T., Alemu, S. G., Añez, A., Anstey, N. M., Awab, G. R., Baird, J. K., Barber, B. E., Borghini-Fuhrer, I., Chu, C. S., D'Alessandro, U., Dahal, P., Daher, A., de Vries, P. J., Erhart, A., Gomes, M. S. M., Gonzalez-Ceron, L., Grigg, M. J., Heidari, A., Hwang, J., Kager, P. A., Ketema, T., Khan, W. A., Lacerda, M. V. G., Leslie, T., Ley, B., Lidia, K., Monteiro, W. M., Nosten, F., Pereira, D. B., Phan, G. T., Phyo, A. P., Rowland, M., Saravu, K., Sibley, C. H., Siqueira, A. M., Stepniewska, K., Sutanto, I., Taylor, W. R. J., Thwaites, G., Tran, B. Q., Tran, H. T., Valecha, N., Vieira, J. L. F., Wangchuk, S., William, T., Woodrow, C. J., Zuluaga-Idarraga, L., Guerin, P. J., White, N. J., & Price, R. N.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2018-09
Volume
18
Issue
9
Pages
1025-1034
ISSN
1473-3099
Cited by
102
References
0
Language
en
Licence
Funders
  • Royal Australasian College of Physicians (1104975)
  • Exxon Mobil Corporation
  • National Health and Medical Research Council
  • Bill and Melinda Gates Foundation (1135820, OPP1054404, OPP1164105)
  • Pan American Health Organization
  • United States Agency for International Development

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. https://app.cochat.ai/papers/10.1016/s1473-3099(18)30348-7
The paper
Commons, R. J., Simpson, J. A., Thriemer, K., Humphreys, G. S., Abreha, T., Alemu, S. G., Añez, A., Anstey, N. M., Awab, G. R., Baird, J. K., Barber, B. E., Borghini-Fuhrer, I., Chu, C. S., D'Alessandro, U., Dahal, P., Daher, A., de Vries, P. J., Erhart, A., Gomes, M. S. M., . . . Price, R. N. (2018). The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(18)30348-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.